We are live on ! Find out more
CRBU icon

Caribou Biosciences

113 hedge funds and large institutions have $457M invested in Caribou Biosciences in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

298% more call options, than puts

Call options by funds: $2.17M | Put options by funds: $545K

125% more capital invested

Capital invested by funds: $203M → $457M (+$254M)

108% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 24

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

9.58% more ownership

Funds ownership: 61.5%71.08% (+9.6%)

6% less funds holding

Funds holding: 120113 (-7)

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

Holders
113
Holders Change
-7
Holders Change %
-5.83%
% of All Funds
1.95%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
14
Increased
50
Reduced
24
Closed
21
Calls
$2.17M
Puts
$545K
Net Calls
+$1.62M
Net Calls Change
+$745K
Name Holding Trade Value Shares
Change
Change in
Stake
PHS
1
PFM Health Sciences
California
$63.3M
BlackRock
2
BlackRock
New York
$47.2M +$3.99M +428,404 +11%
PAMS
3
Pictet Asset Management (Switzerland)
Switzerland
$34.7M +$5.61M +601,671 +22%
APM
4
Avidity Partners Management
Texas
$33.5M +$2.07M +222,600 +8%
Vanguard Group
5
Vanguard Group
Pennsylvania
$26.9M +$5.23M +561,065 +28%
State Street
6
State Street
Massachusetts
$25.3M +$14.9M +1,597,870 +200%
EWM
7
Elmwood Wealth Management
California
$24.9M +$22M +2,364,240 New
RCMU
8
Rokos Capital Management (UK)
United Kingdom
$20.8M
Fidelity Investments
9
Fidelity Investments
Massachusetts
$15.2M -$752K -80,742 -5%
Alkeon Capital Management
10
Alkeon Capital Management
New York
$12.9M +$3.25M +348,542 +40%
Morgan Stanley
11
Morgan Stanley
New York
$12.8M +$5.32M +571,409 +89%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$10.4M +$2.89M +310,597 +46%
FCM
13
Farallon Capital Management
California
$9.46M -$12.2M -1,307,526 -59%
Fidelity International
14
Fidelity International
Bermuda
$9.08M
Assenagon Asset Management
15
Assenagon Asset Management
Luxembourg
$8.44M -$2.89M -310,438 -28%
MC
16
Maverick Capital
Texas
$6.88M
JP Morgan Chase
17
JP Morgan Chase
New York
$6.34M +$855K +91,782 +18%
Goldman Sachs
18
Goldman Sachs
New York
$6M +$3.99M +428,011 +305%
TCM
19
Tekla Capital Management
Massachusetts
$5.98M -$1.23M -132,230 -19%
MSKCC
20
Memorial Sloan Kettering Cancer Center
New York
$5.74M -$606K -65,000 -11%
Northern Trust
21
Northern Trust
Illinois
$5.52M +$681K +73,078 +16%
7IH
22
72 Investment Holdings
Connecticut
$5M
Charles Schwab
23
Charles Schwab
California
$4.21M +$1.78M +191,492 +92%
Adage Capital Partners
24
Adage Capital Partners
Massachusetts
$3.66M -$233K -25,000 -7%
Invesco
25
Invesco
Georgia
$3.32M +$2.76M +296,643 +1,611%

CRBU Hedge Fund Activity: Q3 2022 in Review

113 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q3 2022, worth a combined $457M — up 125% from $203M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CRBU and 14 opened new positions — a net loss of 7 holders — while 24 trimmed existing stakes and 50 added.

The largest buyer was Elmwood Wealth Management, opening a new position worth an estimated $22M. The largest seller was Farallon Capital Management, cutting an estimated $12.2M.

  • 113 institutional investors held Caribou Biosciences (CRBU) as of Q3 2022, down from 120 in Q2 2022.
  • Funds reported $457M of Caribou Biosciences stock for Q3 2022, up 125% quarter-over-quarter.
  • 14 funds opened new Caribou Biosciences positions in Q3 2022 and 21 closed out, a net change of -7 holders.
  • The largest Caribou Biosciences buyer in Q3 2022 was Elmwood Wealth Management, an estimated $22M added.
  • The largest Caribou Biosciences seller in Q3 2022 was Farallon Capital Management, an estimated $12.2M sold.

Based on aggregated 13F filings for Q3 2022.